SHARE:  

View as Webpage

Therapeutic Antibodies Solutions

The latest products & news from ACROBiosystems

TL1A Makes Waves: Merck and Sanofi Step In,

Unveiling a Market Potential of Over $200 Billion

199a5015-f36a-44f6-baa2-8ee332bc6842 image
6c9a3416-0ac5-48ac-95dd-c01756e9e023 image
  • Sanofi and Teva collaborate on novel anti-TL1A therapy (TEV’574) for IBD, with a deal worth up to $1.5 billion.
  • Merck & Co. has agreed to acquire TL1A antibody development pioneer, Prometheus Biosciences, for approximately $10.8 billion.

TL1A and its receptor DR3 belong to the TNF/TNFR superfamily. TL1A, presented by APCs, binds to DR3 on lymphocytes, amplifying T-cell responses and enhancing immune reactions in mucosal tissues. TL1A plays a critical role in inflammation and fibrosis. Modulating TL1A/DR3 signaling may have therapeutic potential for immune-related diseases, like intestinal inflammation.


ACROBiosystems accelerates targeted drug development for intestinal inflammation with high-quality recombinant TL1A and DR3 proteins.

  • High purity verified by SEC-MALS SDS-PAGE
  • TL1A and DR3 high binding activity validated by ELISA/SPR, with a complimentary protocol provided.
  • High batch-to-batch consistency of all product
Inquiry

Vaccine Development Solutions

The latest news from ViruStop, an ACRO brand

387f8d9e-6c63-4d45-bf0f-33abe9b46c63 image

The future of vaccines

- more mRNA vaccines coming soon? 

2cc4c5ab-0a2d-42bb-a13a-8aced676b5ed image

Katalin Kariko of Hungary and Drew Weissman of the United States have won the 2023 Nobel Prize in Physiology or Medicine for their discovery of nucleotide base modifications, the Nobel Prize Committee at the Karolinska Institute in Sweden announced. These findings were the primary factor that enabled the development of effective mRNA vaccines against COVID-19 infection.


The success of mRNA vaccines against COVID-19 may signal a new, more successful, chapter in the continued battle to develop effective preventative measures against other viruses such as RSV. In addition, advances in the characterization, and structural resolution, of the RSV surface fusion glycoprotein have revolutionized RSV vaccine development by providing a new target for preventive interventions. 

Explore our core reagents for RSV Vaccine development>>

Warm tip: Post-Fusion F0 Specific ELISA Kit(RAS-A169) is online, so that your test has a control!

Neuroscience Solutions

The latest news from AneuroTM, an ACROBiosystems brand.

Explore innovative advances in neuroscience with experts.

Learn about cutting-edge research in Alzheimer's, digital biomarkers, and CNS therapeutics. Uncover the opportunities for new drug development and revolutionize the treatment of neurological disorders.

Learn more & Register

Download E-Resources

Core Reagents for Infectious Disease Research

ComboX, A Combination of Universal Solutions

Aneuro - Advance Neuroscience Research

Awards & Certifications